Figure 1.
Figure 1. Bioluminescent imaging results. NSG-immunodeficient mice were inoculated on day 0 with 5 × 105 NALM-6-GL cells and then, on day 3, received 1.5 × 107 CAR-modified T cells as designated. Mock recipients received 1.5 × 107 total cells. Transduction efficiency was ∼ 40% in both CAR groups. Mock-transduced cells were activated and expanded but were not exposed to viral vector. Bioluminescent imaging using standard techniques at the designated time points demonstrates clearance of the leukemia by day 8. All CAR-treated mice were long-term leukemia-free survivors, whereas all mock-treated mice succumbed to leukemia.

Bioluminescent imaging results. NSG-immunodeficient mice were inoculated on day 0 with 5 × 105 NALM-6-GL cells and then, on day 3, received 1.5 × 107 CAR-modified T cells as designated. Mock recipients received 1.5 × 107 total cells. Transduction efficiency was ∼ 40% in both CAR groups. Mock-transduced cells were activated and expanded but were not exposed to viral vector. Bioluminescent imaging using standard techniques at the designated time points demonstrates clearance of the leukemia by day 8. All CAR-treated mice were long-term leukemia-free survivors, whereas all mock-treated mice succumbed to leukemia.

Close Modal

or Create an Account

Close Modal
Close Modal